https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2015-10-21 / Mol Ther Oncolytics 2015;2
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2015-10-21 / Mol Ther Oncolytics 2015;22015-10-21 00:00:002019-02-15 09:22:51Oncolysis by paramyxoviruses: preclinical and clinical studies
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2015-10-20 / Oncotarget 2015 Oct;6(32):33781-90
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2015-10-20 / Oncotarget 2015 Oct;6(32):33781-902015-10-20 00:00:002019-02-15 08:45:06Dendritic cell vaccination with a toll-like receptor agonist derived from mycobacteria enhances anti-tumor immunity
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2015-10-15 / BMC Cancer 2015 Oct;15:708
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2015-10-15 / BMC Cancer 2015 Oct;15:7082015-10-15 00:00:002019-02-15 08:48:27Improving immunological tumor microenvironment using electro-hyperthermia followed by dendritic cell immunotherapy
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
IOZK
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
IOZK2015-10-12 16:50:102019-02-12 16:51:19Bericht von Prof. Dr. Schirrmacher im International Journal of Oncology zu den Erkenntnissen der Tumor-reaktiven T-Zell-Memory im Knochenmark
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2015-10-09 / Cytotherapy 2015 Dec;17(12):1746-62
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2015-10-09 / Cytotherapy 2015 Dec;17(12):1746-622015-10-09 00:00:002019-02-15 08:38:59Validity of combination active specific immunotherapy for colorectal cancer: a meta-analysis of 2993 patients
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2015-10-05 / Expert Opin Biol Ther 2015;15(12):1757-71
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2015-10-05 / Expert Opin Biol Ther 2015;15(12):1757-712015-10-05 00:00:002021-11-15 16:52:53Oncolytic Newcastle disease virus as a prospective anti-cancer therapy. A biologic agent with potential to break therapy resistance
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2015-10-01 / Drug Discov Ther 2015 Oct;9(5):363-71
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2015-10-01 / Drug Discov Ther 2015 Oct;9(5):363-712015-10-01 00:00:002015-10-01 00:00:00Immunotherapy for hepatocellular carcinoma
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2015-10-01 / Anticancer Res. 2015 Oct;35(10):5401-6
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2015-10-01 / Anticancer Res. 2015 Oct;35(10):5401-62015-10-01 00:00:002015-10-01 00:00:00Sensitivity of Human Malignant Melanoma Cell Lines to Newcastle Disease Virus
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2015-10-01 / Nat. Med. 2015 Oct;21(10):1128-38
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2015-10-01 / Nat. Med. 2015 Oct;21(10):1128-382015-10-01 00:00:002015-10-01 00:00:00Natural and therapy-induced immunosurveillance in breast cancer
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2015-10-01 / J. Immunother. 2015 Oct;38(8):330-9
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2015-10-01 / J. Immunother. 2015 Oct;38(8):330-92015-10-01 00:00:002019-02-15 08:51:17Lenalidomide Synergistically Enhances the Effect of Dendritic Cell Vaccination in a Model of Murine Multiple Myeloma
